Cloridrato de propranolol

Betabloqueador não seletivo (β1 e β2). Atravessa barreira hematoencefálica.

1 de dez. de 20241 de

1 cite1×

Gestação:Categoria CRisco não pode ser descartado, usar se benefício justificar

Este medicamento tem dados farmacogenéticos

Configure seus genótipos para ver alertas personalizados de dosagem.

INDICAÇÕES

Adultos

40-160mg

Dividido em 2-3 doses

Adultos

40-320mg

Dividido em 2-3 doses

Nenhuma interação crítica registrada.

Compatível

1 gene with drug interactions

Pharmacogenomics testing may help personalize dosing for this medication. Results depend on patient's genetic profile.

Data source: PharmGKB

Phenotype	Variant	Clinical Implications
Poor Metabolizer	3, 4, 5, 6	-Reduced propranolol metabolism -Higher plasma levels (2-3x increase) -More pronounced beta-blockade effects -Increased risk of bradycardia and hypotension
Ultra-rapid Metabolizer	1xN, 2xN	-Rapid propranolol metabolism -Lower plasma levels -May have reduced efficacy

*Poor Metabolizer: Start with lower doses (10-20mg)
*Poor Metabolizer: Titrate based on heart rate and blood pressure
*Poor Metabolizer: May need dose reduction
*Poor Metabolizer: Monitor for excessive bradycardia
*Ultra-rapid Metabolizer: May need higher doses for effect
*Ultra-rapid Metabolizer: Consider shorter dosing intervals
*Ultra-rapid Metabolizer: Alternative beta-blocker may be considered if poor response